小鼠CD200基因重组腺病毒载体的构建及鉴定

Construction and identification of recombinant adenovirus vector containing mouse CD200 gene

目的：构建携带小鼠CD200基因的重组腺病毒载体,并鉴定其在小鼠胰腺内皮细胞（mile sven 1,MS1）中mCD200基因的表达情况。方法：mCD200基因亚克隆至腺病毒穿梭质粒pYr-adshuttle-4,获得重组质粒pYr-ads-4-mCD200。从该重组质粒上利用LR（attL×attR）特异性同源重组的方法,将mCD200表达框构建至腺病毒骨架质粒pAd/PL-DEST上,获得的重组腺病毒质粒经PacⅠ酶切,转染HEK293细胞,包装成重组腺病毒rAd-4-mCD200,并用酶切和PCR等鉴定。采用TCID 50（tissue cell infectious dosage 50,TCID50）法测定重组腺病毒滴度。同时在HEK293细胞中进行病毒扩增,并感染小鼠内皮细胞MS1,通过荧光显微镜、real-time PCR检测MS1中小鼠CD200基因的表达。结果：PCR鉴定重组腺病毒证实重组腺病毒rAd-4-mCD200构建成功;扩增后检测病毒滴度约为109~1010pfu/ml;荧光显微镜及real-time PCR检测发现该重组腺病毒能在MS1细胞中高效的表达。结论：构建的重组腺病毒rAd-4-mCD200在MS1细胞中成功表达mCD200基因,为下一步开展关于CD200基因免疫抑制调节等相关研究奠定了基础。

Objective：To construct the recombinant adenovirus vector containing mouse CD200 gene and to detect its expression in mice pancreas endothelial cells（mile sven 1,MS1）.Methods：mCD200 gene was subcloned into the shuttle plasmid pYr-adshuttle-4 and recombinant plasmid pYr-ads-4-mCD200 was acquired.After that mCD200 mRNA expression frame was transfered to pAd/PL-DEST adenovirus vector via LR（attL×attR） in vitro homologous recombination from pYr-ads-4-mCD200.Recombinant adenovirus plasmid was digested by PacⅠand transfected into HEK 293 cells and packaged out recombinant adenovirus rAd-4-mCD200,which was identified by digestion and PCR analysis.Virus titer was measured by the tissue cell infectious dosage 50（TCID50） method.Meanwhile,adenovirus was amplified in HEK 293 cells and used to infect MS1 cells.Expression of mCD200 gene was measured by fluorescence microscope and real-time PCR.Results：PCR identification demonstrated the construction of recombinant adenovirus carrying rAd-4-mCD200 was successful and its titer was about 109-1010 pfu/ml after amplification.Through the fluorescence microscope and real-time PCR,recombinant adenoviral vector of mCD200 gene was constructed successfully in the MS1 cells.Conclusions：MS1 cells infected by constructed adenovirus vector rAd-4-mCD200 could express mCD200 successfully and may provide the foundation for the next step to carry out the CD200 gene immunosuppression regulation and other related study.